Critical Kennedy's disease with Guillain-Barré syndrome and respiratory failure: A case report.

Medicine (Baltimore)Sep 25, 2026
Case ReportNeurologyPulmonologyMedical Genetics

Xinran Gao, Kunyao Yu

✦ AI-curated · Sources linked

Case in brief

A 61-year-old man with a 35-year history of Kennedy disease presented with acute respiratory failure, dysphagia, and progressive dyspnea. Genetic testing confirmed spinal and bulbar muscular atrophy, while probable Guillain-Barré syndrome was suspected due to acute deterioration and positive anti-ganglioside antibodies. He received multidisciplinary care, including plasma exchange, and was eventually discharged to rehabilitation after successful extubation and weaning from ventilation.

Diagnostic / clinical pearl

Clinicians should consider the possibility of superimposed treatable neuromuscular disorders in patients with Kennedy disease experiencing acute neurological deterioration.

Why it matters

This case highlights the importance of integrated multidisciplinary management in optimizing outcomes for patients with complex neuromuscular conditions and acute respiratory failure.

Source

PubMed · PMID 42798063

Published in Medicine (Baltimore). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.